Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
NCT05998135

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Led by Emory University · Updated on 2025-09-11

28

Participants Needed

1

Research Sites

189 weeks

Total Duration

On this page

Sponsors

E

Emory University

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

CONDITIONS

Official Title

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • No limit on the number of prior therapies
  • Open to non-English speaking patients
  • Open to patients referred from community practice
Not Eligible

You will not qualify if you...

  • Patients younger than 18 years old
  • Pregnant or breastfeeding patients
  • Patients who are incarcerated
  • Patients unable to provide consent or lacking decision-making capacity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States, 30322

Actively Recruiting

Loading map...

Research Team

N

Namita Khanna, MD, MSPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here